Pearls and Pitfalls in the Diagnosis and Management of Neuromuscular Junction Disorders

ABSTRACT

Myasthenia gravis (MG) is a common autoimmune disorder characterized by the presence of pathogenic antibodies directed against the acetylcholine receptor. Patients present with variable degrees and distribution of fluctuating weakness, at times life-threatening. Clinical manifestations, establishment of diagnosis, the natural history of MG, and therapeutic options are herein reviewed with an emphasis on pearls and pitfalls of clinical relevance. Far less common is Lambert-Eaton syndrome (the myasthenic syndrome), another autoimmune disorder due to the presence of antibodies directed against the PQ-type voltage-gated calcium channels. Clinical features and treatment issues of these and other disorders of neuromuscular transmission are reviewed.

KEYWORD

Myasthenia gravis - Lambert-Eaton syndrome - plasma exchange - immunotherapy of neuromuscular disease - botulism - tick paralysis

REFERENCES

• 1 Howard Jr M F, Lennon V A, Finley J, Matsumoto J, Elveback L R. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis.  Ann N Y Acad Sci . 1987;  505 526-538
• 2 Jaquer L, Weigert C. Beitrage zur Lehre von der Erb'schen krankheit ueber die Erb-sche krankheit (myasthenia gravis).  Neurol Zentralblatt . 1901;  20 594-601
• 3 Grob D, Arsura E L, Brunner N G, Namba T. The course of myasthenia gravis and therapies affecting outcome.  Ann N Y Acad Sci . 1987;  505 472-499
• 4 Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.  Nature Medicine . 2001;  7 365-368
• 5 Walker M B. Case showing the effect of prostigmin on myasthenia gravis.  Proc R Soc Med . 1935;  28 759-761
• 6 Walker M B. Myasthenia gravis: a case in which fatigue of the forearm muscles could induce paralysis of the extraocular muscles.  Proc R Soc Med . 1937;  31 722
• 7 Blalock A, Mason M F, Morgan H J, Riven S S. Myasthenia gravis in tumors of the thymic region: report of a case in which tumor was removed.  Ann Surg . 1939;  110 544-561
• 8 Kennedy F S, Moersch F P. Myasthenia gravis: a clinical review of 87 cases observed between 1915 and the early part of 1932.  Can Med Assoc J . 1937;  37 217
• 9 Oosterhuis H G H J. The natural course of myasthenia gravis: a long term follow up study.  J Neurol Neurosurg Psychiatry . 1989;  52 1121-1127
• 10 Bever Jr T C, Aquino A V, Penn A S. Prognosis of ocular myasthenia.  Ann Neurol . 1983;  14 516-519
• 11 Simpson J A. Myasthenia gravis: a personal view of pathogenesis and mechanism, part 1.  Muscle Nerve . 1978;  1 45-46
• 12 Howard F M, Duane D D, Lambert E H, Daube J R. Alternate-day prednisone: preliminary report of a double-blind controlled study.  Ann N Y Acad Sci . 1976;  274 596-607
• 13 Keesey J, Buffkin D, Kebo D, Ho W, Herrmann Jr C. Patten BM. (Referenced as an article discussant). Plasma exchange alone as therapy for myasthenia gravis.  Ann N Y Acad Sci . 1981;  377 742
• 14 Blalock A. Thymectomy in the treatment of myasthenia gravis: report of 20 cases.  J Thorac Surg . 1944;  13 316-339
• 15 Perlo V P, Arnason B, Poskanzer D. The role of thymectomy in the treatment of myasthenia gravis.  Ann N Y Acad Sci . 1971;  183 308-315
• 16 Buckingham J M, Howard F M, Bernatz P E. The value of thymectomy in myasthenia gravis: computer assisted match study.  Ann Surg . 1976;  184 453-458
• 17 Eaton L M, Clagett O T. Thymectomy in the treatment of myasthenia gravis: results in 72 cases compared with 142 cases.  JAMA . 1950;  142 963-967
• 18 Jaretzki A, Pen A S, Younger D S. Maximal thymectomy for myasthenia gravis.  J Thorac Cardiovasc Surg . 1988;  95 747-57
• 19 Jaretzki A. Thymectomy for myasthenia gravis: analysis of the controversies regarding technique and results.  Neurology . 1997;  48 52S-63S
• 20 Masoaka A, Negaoka Y, Kotake Y. Distribution of thymic tissue in the anterior mediastinum: current procedures in thymectomy.  J Thorac Cardiovasc Surg . 1975;  70 747-754
• 21 Pirskanen R, Matell G, Henze A. Results of transsternal thymectomy after failed transcervical thymectomy.  Ann N Y Acad Sci . 1987;  505 866-867
• 22 Schumm J F, Wietholter H, Fateh-Moghadam A, Dichgans J. Thymectomy in myasthenia with pure ocular symptoms.  J Neurol Neurosurg Psychiatry . 1985;  48 332-337
• 23 Olanow C W, Lane R JM, Roses A D. Thymectomy in late onset myasthenia gravis.  Arch Neurol . 1982;  39 82-83
• 24 Kupersmith M J, Moster M, Bhuiyan S, Warren F, Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis.  Arch Neurol . 1996;  53 802-804
• 25 McQuillen M P. Ocular myasthenia gravis.  Arch Neurol . 1997;  54 229
• 26 Pascuzzi R M, Coslett H B, Johns T R. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients.  Ann Neurol . 1984;  15 291-298
• 27 Finley J C, Pascuzzi R M. Rational therapy of myasthenia gravis.  Sem Neurol . 1990;  10 70-82
• 28 Mertens H G, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents.  Eur Neurol . 1969;  2 323-339
• 29 Matell G, Bergstrom K, Franksson C. Effects of some immunosuppressive procedures on myasthenia gravis.  Ann N Y Acad Sci . 1979;  274 659-676
• 30 Scherpbier H J, Oosterhuis H J. Factors influencing the relapse risk at steroid dose reduction to myasthenia gravis.  Clin Neurol Neurosurg . 1987;  89 145-150
• 31 Hohlfeld R, Toyka K V, Besinger U A, Gerhold B, Heininger K. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine.  Ann Neurol . 1985;  17 238-242
• 32 Miano M A, Bosley T M, Heiman-Patterson T D. Factors influencing outcome of prednisone dose reduction in myasthenia gravis.  Neurology . 1991;  41 919-921
• 33 Myasthenia Gravis Clinical Study Group. A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis: results of the second interim analysis.  J Neurol Neurosurg Psychiatry . 1993;  56 1157-1163
• 34 Palace J, Newsome-Davis J, Lecky B, and the Myasthenia Study Group. A multicenter randomized double-blind trial of prednisolone plus azathioprine versus prednisolone plus placebo in myasthenia gravis.  Neurology . 1996;  46 A332
• 35 Palace J, Newsome-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.  Neurology . 1998;  50 1778-1783
• 36 Tindall R SA, Phillips J T, Rollins J A. A clinical therapeutic trial of cyclosporin in myasthenia gravis.  Ann N Y Acad Sci . 1993;  681 539-551
• 37 Chaudhry V, Cornblath D R, Griffin J W, O'Brien R, Drachman D B. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.  Neurology . 2001;  56 94-96
• 38 Ciafaloni E, Massey J M, Tucker-Lipscomb B, Sanders D B. Mycophenolate mofetil for myasthenia gravis: an open label pilot study.  Neurology . 2001;  56 97-99
• 39 Pinching A J, Peters D K, Newsome-Davis J. Remission of myasthenia gravis following plasma exchange.  Lancet . 1976;  2 1373-1376
• 40 Dau P C, Lindstrom J M, Cassel C K. Plasmapheresis in immunosuppressive drug therapy of myasthenia gravis.  N Engl J Med . 1977;  297 1134-1140
• 41 Keller A J, Urbaniak S J. Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components.  Br J Haematol . 1978;  38 531-540
• 42 Hawkey C J, Newsom-Davis J, Vincent A. Plasma exchange and immunosuppressive drug therapy in myasthenia gravis: no evidence for synergy.  J Neurol Neurosurg Psychiatry . 1981;  44 469-475
• 43 Thorlacius S, Mollnes T E, Garred P. Plasma exchange in myasthenia gravis: changes in serum complement and immunoglobulins.  Acta Neurol Scand . 1988;  78 221-227
• 44 Ronager J, Ravnborg M, Vorstrup S. Clinical effect of high-dose intravenous immunoglobulin compared to plasma exchange in patients with moderate to severe myasthenia gravis.  American Academy of Neurology 51st Annual Meeting: Scientific Program, Scientific Sessions . 1999;  52S 184-185
• 45 Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.  Ann Neurol . 1997;  41 789-796
• 46 Qureshi A I, Choundry M A, Akbar M S. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.  Neurology . 1999;  52 629-632
• 47 Thomas C E, Mayer S A, Gungor Y. Myasthenic crisis: clinical features, mortality, complications and risk factors for prolonged intubation.  Neurology . 1997;  48 1253-1260
• 48 Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis.  Crit Care Med . 1997;  25 1228-1235
• 49 Sanders D B, Massey J M. Randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.  Neurology . 2000;  54 603-607
• 50 Jaretsky A, Barohn R J, Ernstoff R M. Myasthenia gravis: recommendations for clinical research standards.  Neurology . 2000;  55 16-23
• 51 Gronseth G S, Barhon R J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidenced-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology . 2000;  55 7-15
• 52 Pascuzzi R M. Myasthenia gravis: a clinical trials perspective. In: Biller J, Bogousslavsky J, eds. Clinical Trials in Neurological Practice Boston: Butterworth-Heinemann 2001: 93-310
• 53 Engel A G, Ohno K, Sine S M. Congenital myasthenic syndromes: recent advances.  Arch Neurol . 1999;  56 163-167
• 54 Cherington M. Botulism.  Muscle Nerve . 1998;  10 27-31
• 55 Felz M W, Smith C D, Swift T R. A six-year-old girl with tick paralysis.  N Engl J Med . 2000;  342 90-94
• 56 Grattan-Smith P J, Morris J G, Johnston H M. Clinical and neurophysiological features of tick paralysis.  Brain . 1997;  120 1975-1987